NOTCH3 and stroke disorder: We enrolled 81 individuals with NOTCH3 cysteine-altering variants (mean age = 57.2 ± 13.1 years, males/females = 36/45), including 37 preclinical carriers, and 44 symptomatic CADASIL patients who manifested with stroke or cognitive decline.